"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT05147675","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for OA",,"Recruiting","No Results Available","Osteoarthritis|Spinal Arthritis","Biological: AlloRx","Safety (adverse events)|Efficacy: Single Assessment Numeric Evaluation Score (SANE)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-1-MSC-011","December 2021","December 2025","December 2025","December 7, 2021",,"December 7, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05147675"
2,"NCT05152290","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for SCI",,"Recruiting","No Results Available","Spinal Cord Injuries","Biological: AlloRx","Safety (adverse events)|Efficacy: American Spinal Injury Association Impairment Scale (ASIA)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-1-MSC-012","January 2022","January 2026","January 2026","December 9, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05152290"
3,"NCT05158127","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Skin Ulcer",,"Recruiting","No Results Available","Skin Ulcer","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-2-MSC-015","January 2022","January 2026","January 2026","December 15, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05158127"
4,"NCT05147701","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Eye Diseases",,"Recruiting","No Results Available","Eye Diseases|Retinitis Pigmentosa|Glaucoma|Diabetic Retinopathy|Macular Degeneration|Traumatic Optic Neuropathy|Optic Atrophy","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-1-MSC-014","January 2022","January 2026","January 2026","December 7, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05147701"
5,"NCT05147766","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Heart Disease",,"Recruiting","No Results Available","Congestive Heart Failure|Angina","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-1-MSC-017","February 2022","February 2026","February 2026","December 7, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05147766"
6,"NCT05158933","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Ovarian Failure",,"Recruiting","No Results Available","Ovarian Failure","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-2-MSC-012","January 2022","January 2026","January 2026","December 15, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05158933"
7,"NCT05158101","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Stroke",,"Recruiting","No Results Available","Stroke","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-2-MSC-011","February 2022","February 2026","February 2026","December 15, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05158101"
8,"NCT05152394","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Parkinson's Disease",,"Not yet recruiting","No Results Available","Parkinson Disease","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-1-MSC-016","January 2022","January 2026","January 2026","December 9, 2021",,"January 28, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05152394"
9,"NCT05018858","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Lupus",,"Recruiting","No Results Available","Lupus","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-20-ATG-4","February 2022","October 2025","October 2025","August 24, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05018858"
10,"NCT05152381","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Osteoporosis",,"Recruiting","No Results Available","Osteoporosis","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-1-MSC-018","January 2022","January 2026","January 2026","December 9, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05152381"
11,"NCT05018832","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for TBI",,"Not yet recruiting","No Results Available","Traumatic Brain Injury","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-20-ATG-12-4","December 2022","November 2025","November 2025","August 24, 2021",,"July 22, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05018832"
12,"NCT05018845","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for CKD",,"Recruiting","No Results Available","Chronic Kidney Diseases","Biological: AlloRx","Safety (adverse events)|Efficacy: creatinine levels|Efficacy: changes in eGFR","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-20-ATG-22","February 2022","November 2025","November 2025","August 24, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05018845"
13,"NCT05158114","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Testicular Injury and Oligospermia",,"Recruiting","No Results Available","Testicular Injury|Oligospermia","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-2-MSC-013","January 2022","January 2026","January 2026","December 15, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05158114"
14,"NCT05147688","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Pulmonary Diseases",,"Recruiting","No Results Available","Pulmonary Disease|Asthma|Chronic Obstructive Pulmonary Disease","Biological: AlloRx","Safety (adverse events)|Efficacy: Forced vital capacity (FVC)|Efficacy: Pulmonary function test","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-1-MSC-013","December 2021","December 2025","December 2025","December 7, 2021",,"December 7, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05147688"
15,"NCT05003960","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Autism",,"Recruiting","No Results Available","Autism","Biological: AlloRx","Safety (adverse events)|Efficacy: Autism Treatment Evaluation Checklist (ATEC)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-8-ATG-8-02","February 2022","September 2025","September 2025","August 13, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05003960"
16,"NCT05018819","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for CP",,"Recruiting","No Results Available","Cerebral Palsy","Biological: AlloRx","Safety (adverse events)|Efficacy: Gross Motor Function Measure (GMFM)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-11-ATG-11-02","February 2022","November 2025","November 2025","August 24, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05018819"
17,"NCT05003908","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Diabetes",,"Recruiting","No Results Available","Diabetes","Biological: AlloRx","Safety (adverse events)|Efficacy: the level of A1C|Efficacy: the level of C-Peptide|Efficacy: Insulin dose reduction","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-10-ATG-11-01","February 2022","November 2025","November 2025","August 13, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05003908"
18,"NCT05003388","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS",,"Recruiting","No Results Available","Multiple Sclerosis","Biological: AlloRx","Safety (adverse events)|Efficacy: Kurtzke Expanded Disability Status Scale (EDSS)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-8-ATG-9-03","February 2022","October 2025","October 2025","August 12, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05003388"
19,"NCT05003934","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for RA",,"Recruiting","No Results Available","Rheumatoid Arthritis","Biological: AlloRx","Safety (adverse events)|Efficacy: the 28-joint disease activity score (DAS 28)|Efficacy: visual analog scale (VAS)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-8-ATG-10-03","February 2022","September 2025","September 2025","August 13, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05003934"
20,"NCT05003947","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IBD",,"Recruiting","No Results Available","Inflammatory Bowel Diseases","Biological: AlloRx","Safety (adverse events)|Efficacy: The Short Inflammatory Bowel Disease Questionnaire (SIBDQ)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-8-ATG-11-04","February 2022","October 2025","October 2025","August 13, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05003947"
21,"NCT05016804","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Systemic Sclerosis",,"Recruiting","No Results Available","Systemic Sclerosis","Biological: AlloRx","Safety (adverse events)|Efficacy: skin score|Efficacy: Forced vital capacity (FVC)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-10-ATG-12-04","February 2022","November 2025","November 2025","August 23, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05016804"
22,"NCT05018767","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Aging Frailty",,"Recruiting","No Results Available","Frailty","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-11-ATG-12-01","February 2022","November 2025","November 2025","August 24, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05018767"
23,"NCT05016817","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF",,"Recruiting","No Results Available","Idiopathic Pulmonary Fibrosis","Biological: AlloRx","Safety (adverse events)|Efficacy: Forced vital capacity (FVC)|Efficacy: Oxygen saturation test","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-10-ATG-13-08","February 2022","September 2025","September 2025","August 23, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05016817"
24,"NCT05003921","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injection for ALS",,"Recruiting","No Results Available","Amyotrophic Lateral Sclerosis","Biological: AlloRx","Safety (adverse events)|Efficacy: revised ALS functional rating scale (ALSFRS-R)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-7-ATG-7-01","February 2022","September 2025","September 2025","August 13, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05003921"
25,"NCT05152368","Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Trigeminal Neuralgia and Peripheral Neuropathy",,"Recruiting","No Results Available","Peripheral Neuropathy|Trigeminal Neuralgia","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-1-MSC-019","January 2022","January 2026","January 2026","December 9, 2021",,"January 5, 2022","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05152368"
26,"NCT05147779","Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis",,"Recruiting","No Results Available","Erectile Dysfunction|Peyronie's Disease|Interstitial Cystitis","Biological: AlloRx","Safety (adverse events)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATG-1-MSC-015","December 2021","December 2025","December 2025","December 7, 2021",,"December 7, 2021","Medical Surgical Associates Center, St. John's, Antigua and Barbuda",,"https://ClinicalTrials.gov/show/NCT05147779"
27,"NCT05165017","Safety & Efficacy of AlloRx SC® in PTHS Patients",,"Not yet recruiting","No Results Available","Pitt Hopkins Syndrome","Biological: AlloRx Stem Cells®|Other: Placebo control","Safety: Incidence of adverse events improvement) in one or more areas of ailments related to PTHS|Safety: Incidence of serious adverse events|Change in motor function in individuals with PTHS|Change in communication abilities in individuals with PTHS.|Change in sleep habits|Change in gastrointestinal health|Change in breath holding spells|Change in cognition|Change in adaptive function|Change in autistic features|Change in parent assessment of quality of life|Change in global clinical status","Vitro Biopharma Inc.","All","2 Years to 45 Years   (Child, Adult)","Phase 1|Phase 2","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALLORX-PTHS","December 2021","December 2022","December 2023","December 21, 2021",,"December 21, 2021",,,"https://ClinicalTrials.gov/show/NCT05165017"
